Cargando…

Third dose vaccination with mRNA-1273 or BNT162b2 vaccines improves protection against SARS-CoV-2 infection

As of 2021 November 29, booster vaccination against SARS-CoV-2 infection has been recommended for all individuals aged 18 years and older in the United States. A key reason for this recommendation is the expectation that a booster vaccine dose can alleviate observed waning of vaccine effectiveness (...

Descripción completa

Detalles Bibliográficos
Autores principales:	Niesen, Michiel J M, Matson, Robert, Puranik, Arjun, O'Horo, John C, Pawlowski, Colin, Vachon, Celine, Challener, Douglas, Virk, Abinash, Swift, Melanie, Speicher, Leigh, Gordon, Joel, Geyer, Holly, Lenehan, Patrick J, Venkatakrishnan, A J, Soundararajan, Venky, Badley, Andrew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Biological, Health, and Medical Sciences
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9802350/ https://www.ncbi.nlm.nih.gov/pubmed/36713312 http://dx.doi.org/10.1093/pnasnexus/pgac042

Ejemplares similares

Durability analysis of the highly effective mRNA-1273 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022)

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
por: Puranik, Arjun, et al.
Publicado: (2022)

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection
por: Puranik, Arjun, et al.
Publicado: (2022)

FDA-authorized mRNA COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system
por: Pawlowski, Colin, et al.
Publicado: (2021)

Surveillance of Safety of 3 Doses of COVID-19 mRNA Vaccination Using Electronic Health Records
por: Niesen, Michiel J. M., et al.
Publicado: (2022)

Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
por: Puranik, Arjun, et al.
Publicado: (2021)

Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System
por: Pawlowski, Colin, et al.
Publicado: (2021)

SARS-CoV-2 and influenza coinfection throughout the COVID-19 pandemic: an assessment of coinfection rates, cohort characteristics, and clinical outcomes
por: Pawlowski, Colin, et al.
Publicado: (2022)

Enoxaparin is associated with lower rates of mortality than unfractionated Heparin in hospitalized COVID-19 patients
por: Pawlowski, Colin, et al.
Publicado: (2021)

Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19
por: Corchado-Garcia, Juan, et al.
Publicado: (2021)

Real-time analysis of a mass vaccination effort confirms the safety of FDA-authorized mRNA COVID-19 vaccines
por: McMurry, Reid, et al.
Publicado: (2021)

Exploratory analysis of immunization records highlights decreased SARS-CoV-2 rates in individuals with recent non-COVID-19 vaccinations
por: Pawlowski, Colin, et al.
Publicado: (2021)

Pre-existing conditions are associated with COVID-19 patients’ hospitalization, despite confirmed clearance of SARS-CoV-2 virus
por: Pawlowski, Colin, et al.
Publicado: (2021)

Anemia during SARS-CoV-2 infection is associated with rehospitalization after viral clearance
por: Lenehan, Patrick J., et al.
Publicado: (2021)

Vaccination Safety: Don’t Toss the Champagne With the Cork
por: Shah, Aditya, et al.
Publicado: (2021)

Severe acute infection and chronic pulmonary disease are risk factors for developing post-COVID-19 conditions
por: Ghosh, Pritha, et al.
Publicado: (2022)

On the Origins of Omicron’s Unique Spike Gene Insertion
por: Venkatakrishnan, A. J., et al.
Publicado: (2022)

Mapping each pre-existing condition’s association to short-term and long-term COVID-19 complications
por: Venkatakrishnan, A. J., et al.
Publicado: (2021)

Genetic alteration of human MYH6 is mimicked by SARS-CoV-2 polyprotein: mapping viral variants of cardiac interest
por: Anand, Praveen, et al.
Publicado: (2022)

Expanding repertoire of SARS-CoV-2 deletion mutations contributes to evolution of highly transmissible variants
por: Venkatakrishnan, A. J., et al.
Publicado: (2023)

Long-term SARS-CoV-2 RNA Shedding and its Temporal Association to IgG Seropositivity
por: Agarwal, Vineet, et al.
Publicado: (2020)

Long-term SARS-CoV-2 RNA shedding and its temporal association to IgG seropositivity
por: Agarwal, Vineet, et al.
Publicado: (2020)

Quantifying the immunological distinctiveness of emerging SARS-CoV-2 variants in the context of prior regional herd exposure
por: Niesen, Michiel J M, et al.
Publicado: (2022)

Inference from longitudinal laboratory tests characterizes temporal evolution of COVID-19-associated coagulopathy (CAC)
por: Pawlowski, Colin, et al.
Publicado: (2020)

SARS-CoV-2 strategically mimics proteolytic activation of human ENaC
por: Anand, Praveen, et al.
Publicado: (2020)

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar
por: Abu-Raddad, Laith J., et al.
Publicado: (2022)

Healthcare disparities among anticoagulation therapies for severe COVID‐19 patients in the multi‐site VIRUS registry
por: Kirkup, Christian, et al.
Publicado: (2021)

Public health impact of delaying second dose of BNT162b2 or mRNA-1273 covid-19 vaccine: simulation agent based modeling study
por: Romero-Brufau, Santiago, et al.
Publicado: (2021)

Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
por: Razonable, Raymund R., et al.
Publicado: (2021)

Benchmarking evolutionary tinkering underlying human–viral molecular mimicry shows multiple host pulmonary–arterial peptides mimicked by SARS-CoV-2
por: Venkatakrishnan, A. J., et al.
Publicado: (2020)

Plasma IL-6 levels following corticosteroid therapy as an indicator of ICU length of stay in critically ill COVID-19 patients
por: Awasthi, Samir, et al.
Publicado: (2021)

High diversity in Delta variant across countries revealed by genome‐wide analysis of SARS‐CoV‐2 beyond the Spike protein
por: Suratekar, Rohit, et al.
Publicado: (2022)

Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines in U.S. Veterans
por: Dickerman, Barbra A., et al.
Publicado: (2021)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
por: Ballman, Madison, et al.
Publicado: (2021)

Infectious disease physician characteristics and prescription of meropenem in the hospital
por: Challener, Douglas, et al.
Publicado: (2023)

Counties with Lower Insurance Coverage and Housing Problems Are Associated with Both Slower Vaccine Rollout and Higher COVID-19 Incidence
por: Donadio, Gregory, et al.
Publicado: (2021)

Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
por: Thompson, Mark G., et al.
Publicado: (2021)

Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
por: Mavrovouniotis, Ilias, et al.
Publicado: (2023)

The temporal course of T- and B-cell responses to vaccination with BNT162b2 and mRNA-1273
por: Markewitz, Robert, et al.
Publicado: (2022)

In reply—Outcomes of COVID-19 With the Mayo Clinic Model of Care and Research
por: O’Horo, John C., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h5uhvi1bt2km3racu1lntms0fp